120 Participants Needed

Ca-Mg Butyrate for Gulf War Syndrome

(Butyrate Trial)

Recruiting at 3 trial locations
RK
SC
JS
Overseen ByJonathan Skupsky
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications that affect gut motility, immune function, or contain calcium or magnesium butyrate at least 3 months before starting. If you're on steroids, antibiotics, or immunosuppressives, you need to stop them at least 1 month prior. Check with the trial team for specific guidance on your medications.

What data supports the effectiveness of the drug Ca-Mg Butyrate for Gulf War Syndrome?

There is some evidence that magnesium, a component of Ca-Mg Butyrate, may help with asthma symptoms, as seen in studies where magnesium improved symptom scores in asthma patients. Additionally, magnesium has shown effectiveness in reducing symptoms of seasonal allergic rhinitis, which suggests it might have potential benefits for other conditions involving inflammation or immune response.12345

Is Ca-Mg Butyrate safe for humans?

Research on calcium and magnesium supplements shows they are generally well-tolerated in humans, with no significant adverse effects reported in studies, except for potential mild gastrointestinal issues like diarrhea at high magnesium doses.24678

How does the drug Ca-Mg Butyrate differ from other treatments for Gulf War Syndrome?

Ca-Mg Butyrate is unique because it combines calcium and magnesium derivatives with butyric acid, which may offer benefits not seen in other treatments. While magnesium has been studied for its bioavailability and potential neuroprotective effects, the combination with butyric acid in this drug could provide a novel approach to addressing symptoms of Gulf War Syndrome.79101112

What is the purpose of this trial?

The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.

Research Team

SC

Saurabh Chatterjee, PhD

Principal Investigator

VA Long Beach Healthcare System, Long Beach, CA

Eligibility Criteria

This trial is for Gulf War era veterans aged between 40 and 70 who suffer from moderate to severe GWI, as defined by CDC and Kansas criteria. Participants must score less than 30 on the VSF36 physical domain, with no other health conditions that could explain their symptoms.

Inclusion Criteria

I am a Gulf War veteran aged 40-70, in good health before 1990, with symptoms fitting GWI without other explanations.

Exclusion Criteria

Pregnancy or planned pregnancy in the next 6 months
I have a diagnosed inflammatory disorder.
I am taking supplements for gut health or immune support.
See 17 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive microencapsulated butyrate capsules (600 mg twice a day) or placebo for 18 weeks

18 weeks
Regular visits as per trial protocol

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks
Virtual visits

Treatment Details

Interventions

  • Ca-Mg Butyrate
  • Placebo
Trial Overview The trial tests if Ca-Mg Butyrate improves physical function in those with GWI. It measures changes in physical functioning via the VSF-36 survey and examines effects on gut microbiome, gastrointestinal issues, chronic fatigue, inflammation, and cognitive deficits.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cal-Mag-ButyrateExperimental Treatment1 Intervention
Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.
Group II: Placebo for Cal-Mag-ButyratePlacebo Group1 Intervention
Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.

Find a Clinic Near You

Who Is Running the Clinical Trial?

VA Office of Research and Development

Lead Sponsor

Trials
1,691
Recruited
3,759,000+

Miami VA Healthcare System

Collaborator

Trials
18
Recruited
2,400+

VA Salt Lake City Health Care System

Collaborator

Trials
25
Recruited
262,000+

Findings from Research

Oral magnesium supplements showed a significant improvement in FEV1 (forced expiratory volume in one second) at 8 weeks in a study involving 917 patients with mild to moderate asthma, but no improvements were observed at other follow-up periods or in other asthma-related outcomes.
Despite the initial positive effect on lung function, the overall evidence does not support the use of oral magnesium as an effective adjunct treatment for asthma, as it did not significantly impact other measures like FVC, bronchodilator use, or symptoms.
The role of oral magnesium supplements for the management of stable bronchial asthma: a systematic review and meta-analysis.Abuabat, F., AlAlwan, A., Masuadi, E., et al.[2020]
In a study involving 12 atopic subjects, inhaled NAAGA (60 mg three times daily for one week) did not provide any protective effect against allergen-induced bronchoconstriction compared to a placebo.
The treatment was well tolerated, with no adverse effects reported, indicating a good safety profile despite its lack of efficacy.
Effect of an inhaled mast cell stabiliser, N-acetyl-aspartyl-glutamate (Zy15109) on allergen-induced immediate bronchoconstriction.Lai, CK., Gregory, J., Holgate, ST.[2019]
In a study of 55 African-American patients with asthma, it was found that they had significantly lower levels of ionized magnesium compared to a control group, suggesting a potential deficiency that could impact asthma management.
All patients with abnormal levels of divalent ions had their levels corrected with intravenous magnesium, indicating that magnesium therapy may be beneficial for certain asthmatic patients with these deficiencies.
Ionized magnesium levels and the ratio of ionized calcium to magnesium in asthma patients before and after treatment with magnesium.Sinert, R., Spektor, M., Gorlin, A., et al.[2013]

References

The role of oral magnesium supplements for the management of stable bronchial asthma: a systematic review and meta-analysis. [2020]
Effect of an inhaled mast cell stabiliser, N-acetyl-aspartyl-glutamate (Zy15109) on allergen-induced immediate bronchoconstriction. [2019]
Ionized magnesium levels and the ratio of ionized calcium to magnesium in asthma patients before and after treatment with magnesium. [2013]
Magnesium pidolate in the treatment of seasonal allergic rhinitis. Preliminary data. [2016]
Investigation of the effect of short-term change in dietary magnesium intake in asthma. [2019]
Lack of blood pressure effect with calcium and magnesium supplementation in adults with high-normal blood pressure. Results from Phase I of the Trials of Hypertension Prevention (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. [2022]
Lack of effect of oral magnesium on high blood pressure: a double blind study. [2019]
Perspective: Call for Re-evaluation of the Tolerable Upper Intake Level for Magnesium Supplementation in Adults. [2023]
Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. [2022]
Quinolinate and kainate facilitate magnesium penetration into brain tissue. [2019]
11.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Comparative study of magnesium salts bioavailability in rats fed a magnesium-deficient diet]. [2016]
12.United Statespubmed.ncbi.nlm.nih.gov
The behavioral effects of magnesium therapy on recovery of function following bilateral anterior medial cortex lesions in the rat. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security